SECOND AMENDMENT TO THE RESEARCH, DEVELOPMENT AND MARKETING COLLABORATION AGREEMENT BETWEEN ONYX PHARMACEUTICALS, INC., A DELAWARE CORPORATION (“ONYX”), and WARNER-LAMBERT COMPANY, A DELAWARE CORPORATION (“WARNER”).Research, Development and Marketing Collaboration Agreement • March 25th, 2003 • Onyx Pharmaceuticals Inc • Biological products, (no disgnostic substances)
THIS SECOND AMENDMENT (“Second Amendment”) to the RESEARCH, DEVELOPMENT AND MARKETING COLLABORATION AGREEMENT (“Agreement”), having an effective date of July 31, 1997, between Onyx and Warner, which Agreement was first amended on August 2, 1999 to extend its term one year, is entered into and made effective March 1, 2000. Onyx and Warner may be referred to herein individually as “Party,” or collectively, as the “Parties.”
W I T N E S S E T HResearch, Development and Marketing Collaboration Agreement • March 31st, 1998 • Onyx Pharmaceuticals Inc • Biological products, (no disgnostic substances)
RECITALS a. The parties entered into that certain amended and restated Research, Development and Marketing Collaboration Agreement dated October 13, 1997, (the "Collaboration Agreement"), pursuant to which the parties determined to collaborate in...Research, Development and Marketing Collaboration Agreement • May 15th, 1998 • Cocensys Inc • Pharmaceutical preparations
AMENDMENTResearch, Development and Marketing Collaboration Agreement • March 25th, 2003 • Onyx Pharmaceuticals Inc • Biological products, (no disgnostic substances)
AMENDMENT dated December 15, 1997 (this “Amendment”), to the Amended and Restated Research, Development and Marketing Collaboration Agreement between Onyx Pharmaceuticals, Inc., a California corporation (“Onyx”) and Warner-Lambert Company, a Delaware corporation (“Warner”), which Amended and Restated Agreement (the “Agreement”) was executed during July 1997.
RECITALSResearch, Development and Marketing Collaboration Agreement • August 7th, 2000 • Onyx Pharmaceuticals Inc • Biological products, (no disgnostic substances)
ContractResearch, Development and Marketing Collaboration Agreement • May 10th, 2006 • Onyx Pharmaceuticals Inc • Biological products, (no disgnostic substances) • New York
[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES EXCHANGE ACT OF 1933, AS AMENDED.
AMENDMENT #3 TO THE RESEARCH, DEVELOPMENT AND MARKETING COLLABORATION AGREEMENT BETWEEN ONYX PHARMACEUTICALS, INC. AND WARNER-LAMBERT COMPANYResearch, Development and Marketing Collaboration Agreement • November 14th, 2001 • Onyx Pharmaceuticals Inc • Biological products, (no disgnostic substances)
THIS AMENDMENT #3 to the Research, Development and Marketing Collaboration Agreement dated as of July 31, 1997 (“Third Amendment”) is made and entered into on August 6, 2001 (the “Amendment Date”), by and between Onyx Pharmaceuticals, Inc., a Delaware corporation having its principal place of business at 3031 Research Drive, Richmond, California 94806 (“Onyx”), and the Warner-Lambert Company, a Delaware corporation and a wholly-owned subsidiary of Pfizer Inc, having a place of business at 2800 Plymouth Road, Ann Arbor, MI 48105 ("Warner").
CONFIDENTIAL AMENDED AND RESTATED RESEARCH, DEVELOPMENT AND MARKETING COLLABORATION AGREEMENT DATED AS OF MAY 2, 1995 BETWEEN ONYX PHARMACEUTICALS, INC. AND WARNER-LAMBERT COMPANY TABLE OF CONTENTSResearch, Development and Marketing Collaboration Agreement • November 14th, 1997 • Onyx Pharmaceuticals Inc • Biological products, (no disgnostic substances) • New York
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. AMENDED AND...Research, Development and Marketing Collaboration Agreement • March 25th, 1998 • Cocensys Inc • Pharmaceutical preparations • New York
AMENDMENT #3 TO THE AMENDED AND RESTATED RESEARCH, DEVELOPMENT AND MARKETING COLLABORATION AGREEMENT BETWEEN ONYX PHARMACEUTICALS, INC. AND WARNER-LAMBERT COMPANYResearch, Development and Marketing Collaboration Agreement • November 14th, 2001 • Onyx Pharmaceuticals Inc • Biological products, (no disgnostic substances)
THIS AMENDMENT #3 to the Amended and Restated Research, Development and Marketing Collaboration Agreement dated as of May 2, 1995 (“Third Amendment”) is made and entered into on August 6, 2001 (the “Amendment Date”), by and between Onyx Pharmaceuticals, Inc., a Delaware corporation having its principal place of business at 3031 Research Drive, Richmond, California 94806 (“Onyx”), and the Warner-Lambert Company, a Delaware corporation and a wholly-owned subsidiary of Pfizer Inc, having a place of business at 2800 Plymouth Road, Ann Arbor, MI 48105 ("Warner").
AMENDMENT #3 TO THE AMENDED AND RESTATED RESEARCH, DEVELOPMENT AND MARKETING COLLABORATION AGREEMENT between ONYX PHARMACEUTICALS, INC. and WARNER-LAMBERT COMPANYResearch, Development and Marketing Collaboration Agreement • November 9th, 2006 • Onyx Pharmaceuticals Inc • Biological products, (no disgnostic substances)
This Amendment #3 to the Amended and Restated Research, Development and Marketing Collaboration Agreement dated as of May 2, 1995 (“Third Amendment”) is made and entered into on August 6, 2001 (the “Amendment Date”), by and between Onyx Pharmaceuticals, Inc., a Delaware corporation having its principal place of business at 3031 Research Drive, Richmond, California 94806 (“Onyx”), and the Warner-Lambert Company, a Delaware corporation and a wholly-owned subsidiary of Pfizer Inc, having a place of business at 2800 Plymouth Road, Ann Arbor, MI 48105 (“Warner”).
